Medtrum announced Progress on its 300U Tubeless Patch Pump launch in Germany. This follows its Unveiling at DDG 2026 in Berlin and Presence in Germany’s Legal Health Insurance Directory

On 20 July 2026, Medtrum progresses diabetes care in Germany with the introduction of a 300-unit tubeless patch pump. This achievement enhances insulin delivery, increases reimbursement readiness, offers superior patient convenience, encourages digital diabetes management, and supports expansion in the advanced medical device infrastructure.

Medtrum, a global leader in diabetes transformation, announced progress toward launching its 300U tubeless patch pump in Germany, a momentous step toward expanding its insulin delivery solution across Europe. The device was showcased at the DDG 2026 conference in Berlin and added to Germany’s health insurance support directory, improving the chances of reimbursement. The pump's larger reservoir, without tubing, offers greater convenience and resilience for intensive insulin therapy, especially for those with higher insulin requirements. The rising number of diabetes cases is driving demand for easy-to-use, advanced insulin systems.

Inclusion in the directory accelerates accessibility through insurance, strengthening healthcare R&D practices. This change reflects Medtrum’s commitment to expanding in Europe’s large diabetes framework with patient-driven solutions. Its integration with Medtrum’s digital ecosystem enables superior treatment decisions by combining insulin delivery, continuous glucose monitoring, and mobile healthcare tools. This development highlights Medtrum’s focus on innovation and fosters breakthroughs to strengthen its presence and expand treatment in Germany’s healthcare system.

Impact on the Diabetes Care Device Industry 

The global diabetes care devices market size is calculated at USD 68.57 billion in 2025 and is predicted to increase from USD 72.86 billion in 2026 to approximately USD 125.03 billion by 2035, expanding at a CAGR of 6.19% from 2026 to 2035.

According to Precedence Research, as patient preferences transition toward compact, connected devices, manufacturers are accelerating innovations in insulin delivery. Medtrum’s launch of its 300-unit tubeless patch pump is expected to boost the global diabetes device sector by increasing competition in wearable insulin delivery. The launch highlights integration with constant glucose monitoring and mobile application for personalized care, fueling advances in battery life, miniaturization, automation, and AI-assisted dosing. The tubeless design offers better mobility, comfort, and discretion.

R&D investments focus on adherence and patient outcomes, highlighting a move to smart, wearable diabetes devices that combine convenience, precision, and digital connectivity for better disease management. Its larger reservoir suits patients who need higher doses, reducing pump replacements and improving treatment ease.

Impact on the Healthcare Reimbursement Industry

The global healthcare reimbursement market size was accounted for USD 30.6 billion in 2025 and is anticipated to reach around USD 160.63 billion by 2035, growing at a CAGR of 18.03% from 2026 to 2035.

According to Precedence Research, growing willingness to fund advanced diabetes devices that enhance outcomes and quality of life. Medtrum’s 300-unit tubeless patch pump in Germany’s healthcare infrastructure list improves reimbursement, boosting patient access and market potential.

This promotes collaboration among providers, healthcare manufacturers, and payers, aiding the shift to value-based healthcare focused on improved chronic disease management and better patient outcomes. The expanding healthcare reimbursement for clinically and economically beneficial devices makes Germany’s system dominant in Europe, so this could benefit Medtrum’s presence.

Impact on the Chronic Disease Management Industry

The global chronic disease management market size accounted for USD 6.61 billion in 2025 and is predicted to increase from USD 7.51 billion in 2026 to approximately USD 23.18 billion by 2035, expanding at a CAGR of 13.37% from 2026 to 2035.

According to Precedence Research, as chronic diseases increase worldwide, digital solutions are vital to improving health outcomes, where Medtrum’s tubeless patch pump improves digital healthcare and chronic disease management by improving integration between wearable devices and connected healthcare practices. Connected devices yield valuable health data, refining disease management, predictive analytics, and personalized care.

Medtrum’s innovation strengthens the transition toward tech-enabled chronic disease management by combining digital platforms, wearables, and data-driven decision-making. It supports real-time tracking of therapy effectiveness, improves adherence, enables early intervention, and facilitates remote consultations. This lower-level routine promotes interoperability in digital healthcare ecosystem.

Expert Opinion

According to expert opinion, Medtrum’s launch of a 300-unit tubeless patch pump in Germany signifies a key step in diabetes technology, combining larger insulin reservoirs and a tubeless design for convenience, fewer replacements, and relaxed use during intensive therapy. Competition is expected to grow, with a focus on wearable tech, AI, and remote monitoring. This aligns with trends in connected diabetes management, integrating devices with glucose monitoring and digital health platforms to improve personalized care and outcomes.

This highlights the importance of patient-based innovation, digital connectivity, and reimbursement in advancing diabetes treatment and access to insulin devices. Enclosure in Germany’s health insurance directory is crucial, as it accelerates implementation and strengthens Medtrum’s competitive edge within Europe’s domestic framework. Success depends on innovation, reimbursement, patient education, doctor acceptance, cybersecurity, and system integration. Additionally, Germany’s reimbursement system delivers Medtrum an opportunity to demonstrate its benefits in Europe.